Advancements in Epigenetics have certainly given us huge breakthroughs in drug discovery, development and effective diagnosis of diseases. Scientists are working towards making new developments and address challenges in epigenetics for cancer, neurodegenerative diseases and other ailments. The Epigenetics Discovery Congress will provide a platform to such scientists to present their work, learn what their peers are doing, share experiences and overcome challenges that the industry is facing.....

1. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
11
 Review the importance of the strongly growing epigenetic market
 Discuss the latest epigenetic breakthroughs in your field of epigenetic studies
 Explore new avenues to network and showcase your epigenetic research work and discoveries
 Discuss the use of Biomarkers as a tool for achieving optimal detection
 Network with your academic and industry colleagues to brainstorm on latest epigenetic application
 Review the latest epigenetic tools and technologies available in the market to aid your research
Why Attend?
2nd Annual
Epigenetics Discovery
Congress
Novel Inhibitors & Emerging Targets for Drug Discovery
8th
- 9th
September 2016, London, UK
MnM CONFERENCES
Epigenetics has flourished to become one of the most revolutionary areas of science over the past decade. Also, advances in the understanding
of epigenetic processes, have led to a burst in interest in this area as a potential source of new targets for the discovery of medicines.
While the promise of epigenetics is significant, it also presents some interesting challenges like pathways and mechanisms underlying epigenetics,
using right screening platforms, bottlenecks in translational and clinical phase, collating epigenetics data with proper analysis and finding the
right biomarkers.
At the 2nd
Annual Epigenetics Discovery Congress, which will be held on 8-9 September 2016 in London, UK aims to provide a
platform for researchers, academics and industry professionals working in epigenetic research to avail an opportunity & explore the potential of
epigenetics to contribute towards novel and existing therapeutics, current progress and trends in the inclusion of epigenetics in drug discovery
and development.
Along with the advancements in technologies and solutions, the conference will also focus on highlighting some of the emerging trends in terms of
drug discovery with respect to evolving targets, inhibitors, biomarkers and clinical success of epigenetics across various diseases.

2. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
2
Gold Sponsors:
Silver Sponsors:
Sponsor/Exhibitors:
Supporting Association:
THE EPIGENETICS SOCIETY
Media Partners:

3. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
3
Speakers:
Advisory Panel:
Dr. Tamara Maes
Chief Scientific Officer,
Oryzon, Spain
Dr. Paola B. Arimondo
Research Director,
CNRS EtaC, France
Dr. Hajji Nabil
Lecturer in epigenetics and
translational oncology, Imperial
College London, UK
Prof. A. Ganesan
Professor of Chemical Biology
University of East Anglia,
Norwich, UK
Dr. Brian Lohse
Associate Professor, EpiDiscoverY,
Faculty of Health and Medical
Sciences, Department of Drug Design
and Pharmacology, University of
Copenhagen, Denmark
Jenny Southgate
Professor of Molecular Carcinogenesis
Director, Jack Birch Unit,
Department of Biology,
University of York, UK
Prof. Dr. Gianluca Sbardella
Associate Professor of
Medicinal Chemistry, Head of
EpigeneticMedChemLab
Università di Salerno, Italy
Dr. Matthew Suderman
Senior Research Associate in
Epigenetics and Social Science
University of Bristol, UK
Prof. Guro Elisabeth Lind
Group leader Epigenetics, Department
of Molecular Oncology, Institute for
cancer research, Oslo University
Hospital, Norway
Dr. Manfred Koegl
Director Oncology Research
Boehringer Ingelheim, Vienna,
Austria
Dr. Tobias A. Knoch
Group Leader Biophysical Genomics,
Cell Biology & Genetics
Erasmus MC, Rotterdam,
The Netherlands
Dr. Gian Gaetano Tartaglia
Group Leader, Gene Function &
Evolution, Centre for Genomic
Regulation (CRG), Barcelona,
Spain
Prof. Irene Maeve Rea
MD, BSc (Hons), FRCP, FRCP(Ed), FHEA
| Professor Emeritus School of Medicine,
Dentistry and Biomedical Science
Queens University Belfast | Visiting
Professor, NI Centre for Translational
Research, Ulster University
Prof. Dr. F.J. (Frank) Dekker
Associate professor, Medicinal
Chemistry, University of
Groningen, Netherlands
Prof. Stephen J Shuttleworth
Chief Scientific Officer
Karus Therapeutics Ltd, England
Dr. Richard Chesworth
Senior Vice President Molecular
Discovery
Epizyme, USA
Prof. Richard Meehan
Programme Leader, Chromosomes
and Gene Expression MRC Human
Genetics Unit MRC IGMM,
University of Edinburgh, UK
Prof. Rosalind M John
Division Leader for Pathophysiology
and Repair
Cardiff School of Biosciences, UK
Prof. Dr. Reinhard Stöger
Associate Professor in Epigenetics
University of Nottingham,
England
Dr. Moshe Szyf
Glaxo Smith Kline and James McGill
Professor, Department of Pharmacology
and Therapeutics, McGill University
Medical School, Canada
Prof. Dr. Manon van Engeland
Dept. of Pathology, GROW-School for
Oncology and Developmental Biology,
Maastricht University Medical
Center, Netherlands
Dr. Paola B. Arimondo
Research Director
CNRS EtaC, France
Dr. Tamara Maes
Chief Scientific Officer
Oryzon, Spain
Dr. Daniel Vitt
CSO
4SC AG, Germany

4. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
4
Conference Day One, Thursday, 8th
September 2016
08:00 Registration and Refreshments
08:50 MnM Conferences’ Welcome Address
08:55 Opening remarks by the Chair
Developmental Biology and Environment
09:00 Keynote address: Epigenetic regulation of the tumour micro environment (TME) - immuno oncology meets
epigenetics
• 4SC-202 is a new clinical stage epigenetic regulator of the TME
• Enhanced T-cell infiltration in tumours may offer a unique clinical boost of responses to checkpoint inhibitors
• Further approaches of epigenetic immune regulation - beyond HDAC inhibitors
Dr. Daniel Vitt, Vorstand, CSO, 4SC AG, Germany
09:25 Epigenetic profiling and environmental challenge
• 5mC/5hmC profiling tracks environmental exposure in model systems
• Allows identification of potential epigenetic predictors of end point pathologies
• Studying the effects of environmental triggers on the epigenome will enable identification of novel biomarkers
Prof. Richard Meehan, Programme Leader, Chromosomes and Gene Expression, MRC Human Genetics Unit MRC IGMM,
University of Edinburgh, UK
09:50 Stability and flux of DNA methylation patterns
• Genomic programs regulating energy balance evolved to be buffered or ‘canalised’ against genetic variation
• Large genetic regulatory networks can acquire novel epigenetic states in response to environmental challenges
• A new metric to quantify and compare epigenetic flexibility and stability across loci, cell types, and developmental stages
Prof. Dr. Reinhard Stöger, Associate Professor in Epigenetics, University of Nottingham, England
10:15 Presentation by NuGEN
10:45 Morning Refreshments | Networking | Poster presentation | One to One meetings
11:30 Environmental programming of maternal care and offspring behaviour by an epigenetic mechanism
• Prenatal environment and the developing placental epigenome
• Placental function and fetal growth
• Dual programming of maternal care and offspring behaviour
Prof. Rosalind M John, Division Leader for Pathophysiology and Repair, Cardiff School of Biosciences, UK
Translational Epigenetics
11:55 Epigenetic regulation of epithelial homeostasis: an emerging story of health and disease
• Urothelium is a transitional epithelium that functions as a self-repairing, urinary barrier within the bladder and associated urinary tract.
• I will present experimental evidence that at the cellular level, the homeostasis of human urothelium is regulated epigenetically
• I will further consider how local and environmental factors effecting epigenetic deregulation can create an imbalance in tissue
homeostasis, with chronic ulceration versus cancer at the extremes of chronic bladder disease
Prof. Jenny Southgate, Professor of Molecular Carcinogenesis, Director, Jack Birch Unit, Department of Biology, University of York, England
12:20 Presentation by Cell Signalling
12:50 Lunch | Networking | Poster presentation | One to One Meetings
13:50 Presentation by Roche/Kapa Biosystems Ltd.

5. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
5
Clinical Epigenetics and Biomarkers
14:15 Findings in DNA methylation measured across the life-course in a large well-characterized human cohort
• Prenatal biomarkers that remain and disappear
• Static and changing biomarkers of phenotype
• Genetic influences and causal applications
Dr. Matthew Suderman, Senior Research Associate in Epigenetics and Social Science, University of Bristol, UK
14:40 DNA methylation biomarkers for early and non-invasive detection and monitoring of bladder cancer
• Using methylome sequencing (RRBS) to identify high performing DNA methylation biomarkers specific for bladder cancer
• Leveraging biomarkers to reduce the economic costs of bladder cancer
Prof. Guro Elisabeth Lind, Group leader Epigenetics, Department of Molecular Oncology, Institute for cancer research,
Oslo University hospital, Norway
15:05 Genetics or Lifestyle: Is Epigenetics the Missing link in the Longevity Phenotype?
• Human longevity is a complex trait and increasingly we recognise that both genes and lifestyle interact in the longevity
phenotype.
• Family clusters of nonagenarian and centenarian siblings, who show both exceptional age-span and health-span are likely to
have inherited facilitatory gene groups but also have nine decades of life experiences and behaviours which have interacted
with their genetic profiles.
• Although much remains to be discovered, this lecture will discuss some of the epigenetic and environmental factors which
appear important in good quality longevity and link known epigenetic mechanisms to themes identified by nonagenarians
themselves related to their longevity.
Prof. Irene Maeve Rea, Emeritus Professor School of Medicine, Dentistry and Biomedical Science, Ulster University, Ireland
15:30 Afternoon Refreshments | Poster Presentation | Networking | One to One Meetings
16:15 Solution Provider Presentation; contact steve.h@mnmconferences.com
16:45 DNA methylation markers for management of cancer: pitfalls and perspectives
• Discovery of DNA methylation markers
• Implementation of methylation markers into clinical practice
• Pitfalls and perspectives
Prof. Dr. Manon van Engeland, Dept. of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht
University Medical Center, Netherlands
17:10 Decoding the 3D Multi-Loop Aggregate/Rosette Chromatin Architecture, Dynamics, and Functional Epigenetics of
Genomes
• Novel combination of chromosome interaction capture (T2C) and fluorescence correlation spectroscopy (FCS)
• Final architecture and dynamics of genome organization
• The tight entanglement of sequence, structure, and functional epigenetics
Dr. Tobias A. Knoch, Group Leader Biophysical Genomics, Cell Biology Genetics, Erasmus MC, Rotterdam, The
Netherlands
17:35 Closing Remarks by the Chair
17:45 Networking and Drinks Reception

6. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
6
Conference Day Two, Friday, 9th
September 2016
08:15 Registration and Refreshments
08:50 MnM Conferences’ Welcome Address
08:55 Opening remarks by the Chair
09:00 Keynote: Drug Discovery and HMTs
• Overview of Histone Methyl transferases
• Drug discovery of HMTs
• Clinical Data of HMTs so far
Dr. Richard Chesworth, Senior Vice President Research, Epizyme, USA
Epigenetics Inhibitors and Emerging Targets
09:25 KATching lysine acetylations in inflammation
• Role of lysine acetylation in inflammation
• Development of histone acetyltransferase inhibitors
• Selective HDAC inhibitors in inflammation
Prof. Dr. Frank Dekker, Associate professor, Medicinal Chemistry, University of Groningen, Netherlands
09:50 Targeting DNA methylation in cancer cells with non-nucleoside inhibitors
• We have designed novel non-nucleoside inhibitors of DNA methyltransferases able to demethylate and reactive tumor
suppressor genes.
• We applied three chemical strategies: High-Throughput Screening of chemical libraries, rational drug design based on
molecular modeling and the pharmacomodulation of known inhibitors.
• The cellular consequences of this DNA demethylation are studied in comparison to nucleoside inhibitor decitabine.
Dr. Paola B. Arimondo, CNRS, ETaC, France
10:15 Panel discussion
Fostering the culture of collaborations between industry and academic researchers to deliver innovation, translation and impact of
epigenetics on a global scale
• Nurturing translational research
• Initiating drug discovery projects in collaboration with industry
• Improving clinical development
-Dr. Moshe Szyf, Glaxo Smith Kline and James McGill Professor, Department of Pharmacology and Therapeutics,
McGill University Medical School, Canada
-Prof. Jenny Southgate, Professor of Molecular Carcinogenesis, Director, Jack Birch Unit, Department of Biology,
University of York, England
-Dr. Richard Chesworth, Senior Vice President Research, Epizyme, USA
10:45 Morning Refreshments – Networking – Poster presentation and One to One meetings
11:30 Solution Provider Presentation; Please contact Steve Hambrook at steve.h@mnmconferences.com
12:00 Strategies to identify new inhibitor scaffolds for Histone Demethylases and Methylases
• Strategies to discover new scaffolds: small molecules and peptides
• DNA encoded peptide libraries
• Fluorescence Assay development and testing on epigenetic targets
Dr. Brian Lohse, Associate Professor, EpiDiscoverY, Faculty of Health and Medical Sciences, Department of Drug Design and
Pharmacology, University of Copenhagen, Denmark
12:25 Is two better than one? Multitarget epigenetic inhibitors
• Dual HDAC plus kinase inhibitors
• Dual HDAC inhibitor plus receptor ligand
• Dual epigenetic targeting
Prof. A. Ganesan, Professor of Chemical Biology, University of East Anglia, Norwich, UK

7. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
7
MnM CONFERENCESMnM CONFERENCES
12:50 Probing genome readers: the generation of an in vivo active bromodomain inhibitor for BRD9
• The BAF complex is a potential target in cancer therapy
• Structure based drug design of a selective inhibitor of BRD9
• On-target chemical inhibition of Brd9 limits the proliferation of acute myeloid leukemia cells
Dr. Manfred Koegl, Director Oncology Research, Boehringer Ingelheim, Vienna, Austria
13:15 Lunch – Networking – Poster presentation and One to One Meetings
14:15 Presentation by Diagenode
Cancer and Neurodevelopment
14:45 Targeting DNA methylation in neuropsychiatric disease; instructions from cancer epigenetics
• DNA methylation mediating the impact of early exposures on behavioral phenotypes
• Strategies of epigenetic therapeutics in cancer guiding approaches to neuropsychiatry
• Epigenetic strategies towards treatment of behavioral disorders: addiction as a model
Dr. Moshe Szyf, Glaxo Smith Kline and James McGill Professor, Department of harmacology and Therapeutics,
McGill University Medical School, Canada
15:10 Development of LSD1 inhibitors for the treatment of oncological and neurodegenerative disease
• Development of ORY-1001 and ORY-2001
• Identification of the drugs’ modes of action
• Status of ongoing clinical research
Dr. Tamara Maes, Chief Scientific Officer, Oryzon, Spain
15:35 Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment
and Solid Tumor Immunotherapy
• Orally-active, selective small molecule HDAC6 inhibitor
• Cancer Immunotherapy
Prof. Stephen Shuttleworth, CSO, Karus Therapeutics, UK
16:00 Afternoon Refreshments | Poster Presentation | Networking
16:40 A “library-on-library” screening approach to identify small-molecule ligands of methyl-lysine reader proteins
• Methyllysine readers
• Chemical probes
• Protein arrays
Prof. Dr. Gianluca Sbardella, Associate Professor of Medicinal Chemistry, Head of EpigeneticMedChemLab, Università di
Salerno, Italy
Bioinformatics Development in Epigenetics
17:05 A computational approach for identification of protein-RNA interactions uncovers direct binders of Xist lncRNA
• Global Score algorithm to calculate interactions of proteins and lncRNAs at nucleotide and amino acid resolution
• Investigating protein binding to the Xist lncRNA, which orchestrates X Chromosome inactivation
• Validating calculations by means of enhanced individual nucleotide CLIP method (eCLIP)
• Testing method against a number of nucleotide-binding proteins
Dr. Gian Gaetano Tartaglia, Group Leader, gene Function Evolution, Centre for Genomic Regulation (CRG), Barcelona, Spain
17:30 Closing Remarks by the Chair
17:35 End of Conference